You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Wind Turbine Clutter Mitigation

    SBC: MATRIX RESEARCH INC            Topic: AF12BT05

    ABSTRACT: Matrix and CSU are poised to develop algorithms to suppress radar WTC while preserving signals from targets of interest such as aircraft and weather. Our processing approach will be capable of utilizing radar data from either stationary- or scanning-mode ground-based systems. We will work closely with our transition partner to develop a Phase II transition plan to integrate our approac ...

    STTR Phase II 2014 Department of DefenseAir Force
  2. Ultra-High Density Ion Propulsion From Ionic Liquids

    SBC: BUSEK CO., INC.            Topic: AF11BT10

    ABSTRACT: Busek Co. Inc. and Massachusetts Institute of Technology (MIT) propose to explore the physical limits of ionic liquid propulsion via development of new theory to explain effects of close packing emission density and to predict performance limits. The research is motivated by observations and tests demonstrating that emission from 2-dimensional porous surfaces yields order of magnitude g ...

    STTR Phase II 2014 Department of DefenseAir Force
  3. Transdermal Naltrexone for Opiate Addiction and Alcoholism

    SBC: ALLTRANZ, INC.            Topic: NIDA

    DESCRIPTION (provided by applicant): According to the National Survey of Drug Use and Health (NSDUH) of 2008, 7.2 million Americans are in need of treatment for Substance-Related Disorders (SRDs), and a large proportion of those need treatment for opiate pain reliever, heroin, and alcohol addiction. Naltrexone (NTX), an opioid antagonist, is currently used in oral tablet form to help maintain opio ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Therapeutic Utility of renalase and renalase peptides in cisplatin-mediated renal

    SBC: BESSOR PHARMA, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): Cisplatin is a cornerstone therapy for a number of cancers including testicular, bladder, ovarian and lung. It is also used to treat cancers in children. In all cases there is a high incidence of acute kidney injury (AKI) that can also lead to later stage kidney damage. This risk limits its use. We have found in pilot studies that renalase, or peptide fragment ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Targeting DNA damage response pathways for the treatment of advanced lung cancer

    SBC: CUMBERLAND PHARMACEUTICALS, INC.            Topic: NIEHS

    DESCRIPTION (provided by applicant): There is an urgent, unmet need for novel therapeutic approaches that are efficacious against lung cancer. Ranking first among cancer deaths in the U.S., this disease has 5-year relative survival rates of lt20%. Most lung cancers are non-small cell (NSCLC, 85% of cases). Curative surgery is not an option for the 80% of NSCLC patients who present with advanced s ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Stabilization of Therapeutic Peptides by Non-Perturbative Chemical Modification

    SBC: VERAQUEL TECHNOLOGIES, INC.            Topic: NIDDK

    DESCRIPTION (provided by applicant): Type 2 diabetes is a particularly debilitating disease and is endemic for a large proportion of the world's population. The unmet challenges in disease management are the lack of long-term efficacy in reducing hyperglycemia and the inability to stop progression. Glucagon-like peptide-1 (GLP-1), a natural gut hormone, provides a platform for therapeutics to ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Security in Cyber-Physical Networked Systems

    SBC: TENET 3, LLC            Topic: AF13AT05

    ABSTRACT: This proposal is organized around a system decomposition (break the system down to understand and exploit) then composition (rebuild the system with improved defensive measures) methodology. The first step to understanding a system is gathering all associated documentation. Then based on that insight the system is decomposed by discovering susceptibilities (inherent weaknesses) and a ...

    STTR Phase I 2014 Department of DefenseAir Force
  8. Secure Efficient Cross-domain Protocols

    SBC: INFOBEYOND TECHNOLOGY LLC            Topic: AF13AT08

    ABSTRACT: Coordinating and sharing information across multi-level security (MLS) networks are of great interest in many military applications. However, it is very challenging to accomplish those goals due to the heterogeneous security classifications of different network domains. The recent proposed cross-domain solutions (CDS) provide initial steps to make such applications possible. However, th ...

    STTR Phase I 2014 Department of DefenseAir Force
  9. Representation and Inference for Developing Deep Language Engines (RIDDLE)

    SBC: CHARLES RIVER ANALYTICS, INC.            Topic: AF13AT11

    ABSTRACT: Intelligence analysts need to process large amounts of text information to form an understanding of a topic of interest. The sheer amount of information can be overwhelming, so automated text analytics that assist with filtering, information extraction, and document understanding, can be highly beneficial. Deep natural language processing (NLP) applications require both structural knowl ...

    STTR Phase I 2014 Department of DefenseAir Force
  10. Prevention of erectile dysfunction following prostate cancer radiotherapy

    SBC: HUMANETICS CORP            Topic: NCI

    DESCRIPTION (provided by applicant): The aim of this proposal is to evaluate BIO 300 as an effective therapy to prevent and/or mitigate the erectile dysfunction (ED) that is commonly observed following radiotherapy (RT) for prostate cancer. Prostate cancer is the most common cancer among men in the United States. Approximately half of prostate cancer patients will undergo RT as a part of thei ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government